By restoring coronary flow, thrombolytic therapy for acute myocardial infarction diminishes infarct size and left ventricular dysfunction, resulting in better early and late outcome. Thrombolytic therapy has, however, an inherent early risk, that of intracranial hemorrhage and, possibly, myocardial rupture. An effective strategy in reducing this early risk has not so far been available, but lowering of blood pressure and reduction of myocardial contractility may be candidates for further study aiming to fight these often fatal complications of a life-saving therapy for acute myocardial infarction.
VerstraeteM.Thrombolytic therapy in acute myocardial infarctionCirculation1990; 82 (suppl II):II96–II109.
2.
VerheugtFWAMeijerALagrandWKVan EenigeMJ.Reocclusion, the flipside of coronary thrombolysisJ Am Coll Cardiol1996; 27:766–773.
3.
GoreJMGrangerCBSimoonsMLSloanMAWeaverWDWhiteHDStroke after thrombolysis: Mortality and functional outcomes in the GUSTO-1 trialCirculation1995; 92:2811–2818.
4.
Fibrinolytic Therapy Trialist's Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trial of more than 1,000 patientsLancet1994; 343:311–322.
5.
BoschXTherouxPWatersDDPelletierGBRoyD.Early postinfarct ischemia: Clinical, angiographic, and prognostic significanceCirculation1987; 75:988–995.
6.
VerstraeteMArnoldAERBleifeldWHBrowerRWCollenDDe BonoDPAcute coronary thrombolysis with recombinant human tissue-type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rateAm J Cardiol1987; 60:231–237.
7.
BoisselJPCastaigneAMercierCLionLLeizoroviczVentricular fibrillation following administration of thrombolytic therapy: The EMIP experienceEur Heart J1996; 17:213–221.
8.
MaynardCWeaverWDLambrewCBowlbyLJRogersWJRubisonRM.Factors influencing time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction)Am J Cardiol1995; 76:548–552.
9.
SimoonsMLMaggioniAPKnatterudGLeimbergerJDDe JaegerePVan DomburgRIndividual risk assessment for intracranial haemorrhage during thrombolytic therapyLancet1993; 342:1523–1528.
10.
GUSTO Investigators.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarctionN Engl J Med1993; 329:673–682.
11.
GUSTO Angiographic Investigators.The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarctionN Engl J Med1993; 329:1615–1622.
12.
HonanMBFarrellPEReimerKACaliffRMMarkDBPryorDBCardiac rupture, mortality and the timing of thrombolytic therapy: A *meta-analysisJ Am Coll Cardiol1990; 16:359–367.
13.
BeckerRCCharlesworthAWilcoxRGHamptonJRSkeneAGoreJM.Cardiac rupture associated with thrombolytic therapy: Impact of time to treatment in the Late Assessment of Thrombolytic therapy (LATE) studyJ Am Coll Cardiol1995; 25:1063–1068.
14.
WallRCCaliffRMBlankenshipJTalleyJDTannenbaumMSchwaigerMIntravenous fluosol in the treatment of acute myocardial infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 TrialCirculation1994; 90:114–120.
15.
Collaborative Organisation for RheothRx Evaluation (CORE).Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarctionCirculation1997; 96:192–201.
16.
WoodsKLFletcherSRoffeCHaiderY.Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)Lancet1992; 339:1553–1558.
17.
Fourth International Study of Infarct Survival Collaborative Group.ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarctionLancet1995; 345:669–685.
18.
BaxterGFSumurayMSWalkerJM.Infarct size and magnesium: Insights into LIMIT-2 and ISIS-4 from experimental studiesLancet1996; 348:1424–1426.
19.
RobertsRRogersWJMuellerHLambrewCTDiverDJSmithHCImmediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial infarction (TIMI) II-B studyCirculation1991; 83:422–437.
20.
BarronHVRundleACGoreJMGurwitzJ.Reduction of intracranial hemorrhage associated with immediate beta-blocker therapy in patients with acute myocardial infarction treated with tissue plasminogen activator [abstract]J Am Coll Cardiol1998; 31 (suppl A):371 A.
21.
Gruppo per lo Studio della Sopravvivenza nell'Infarto Miocardico.GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-weeks mortality and ventricular function after acute myocardial infarctionLancet1994; 343:1115–1122.
22.
SwedbergKHeldPKjekhusJRasmussenKRydenLWedelH.Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study-2 (CONSENSUS-2)N Engl J Med1992; 327:678–684.
23.
ISIS-1 (First International Study of Infarct Survival) Collaborative Group.Mechanism for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1Lancet1988; i:921–923.
24.
The International Study Group.In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarctionLancet1990; 336:65–71.
